Chronic Obstructive Pulmonary Disease (COPD) - PowerPoint PPT Presentation


PPT – Chronic Obstructive Pulmonary Disease (COPD) PowerPoint presentation | free to download - id: 4a8855-NmMzZ


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation

Chronic Obstructive Pulmonary Disease (COPD)


... damage by protease enzymes Pathophysiology Airflow limitation related to small airway and parenchymal disease Chronic Bronchitis ... acute asthma attack With ... – PowerPoint PPT presentation

Number of Views:729
Avg rating:3.0/5.0
Slides: 68
Provided by: JohnANo
Learn more at:


Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)
  • John Noviasky, PharmD

  • Not reversible Limitation of Expiratory Airflow
  • Progressive and associated with abnormal
    inflammatory response of lungs to noxious
  • COPD most commonly refers to chronic bronchitis
    and emphysema (NOT Asthma)

  • 16 million have COPD
  • 14 million chronic bronchitis
  • 2 milion have emphysema
  • 14 million physician visits and 600k
  • 30 billion dollars/year
  • Disabling disease
  • Chronic Bronchitis - 12 days/yr
  • Emphysema - 68 days/yr

  • 4th leading cause of death
  • 107k in 1998, not including deaths from pneumonia
    and flu which are COPD complications
  • Disease can vary from chronic productive cough to
    severe, disabling dyspnea

Risk Factors
  • EnvironmentalOccupational
  • Grain, coal, asbestos, Pollution
  • Behavioral
  • 20 of smokers develop COPD
  • Genetic-Alpha1-antitrypsin deficiency (1),
    disease at young age
  • Other - Asthma, respiratory infections

Smoking-(figure 24-1)
  • Accelerated loss of lung function
  • gt35yo FEV1 decline about 20-30ml/yr
  • IF smoking, then 50-120ml/yr
  • Not all smokers get COPD, protective mechanism
    unknown (genetic?)
  • Smoke-
  • increases and activity of secretory cells
  • attracts neutrophils/macrophages - destructive
    enzymes released

Smoking-(figure 24-1)
  • Releases Oxygen Free radicals
  • increased concentration of inflammatory mediators
    and inhibit antiprotease activity
  • sustains chronic inflammation and susceptibility
    to damage by protease enzymes

  • Airflow limitation related to small airway and
    parenchymal disease
  • Chronic Bronchitis
  • Inflammation of Bronchioles
  • Mucus Hypersecretion
  • Presence of chronic productive cough for 3
    months/yr over 2 years (not asthma, not CHF,
  • Figure 24-2

  • Emphysema
  • Abnormal permanent enlargement of airspaces
    distal to terminal bronchioles, accompanied by
    destruction of their walls
  • Loss of elastic recoil and surface area for gas
  • Figure 24-2

Large vs Small Airways
  • Large airways (tracheabranchs of bronchi)
  • AKA Central airways
  • Location of airway wall inflammation and
    hypersecretion seen in chronic bronchitis
  • As response to inflammation
  • increase in s (hyperplasia) and enlargement
    (hypertrophy) of submucosal glands and goblet
    cells which produce mucus

Large vs Small Airways
  • Smaller bronchi down to terminal bronchioles make
    up peripheral airways and site of increased air
    resistance seen in asthma and chronic bronchitis
  • IF just bronchitis and mucus production then
    still no airflow impairment (smokers cough) and
    little effect on pulmonary function testing
  • With prolonged inflammation, edema, mucus
    secretion- airway narrowing and airflow

Large vs Small Airways
  • Increased Mucus - excellent medium for recurrent
    infections - lead to further damage
  • Smokers Mucus - looks like a blanket
    compared to normal gel-like substance
  • Increased mucus combined with impaired ciliary
    function-reduced mucociliary clearance, pooling
    of secretions and increased trapping of
    bacteria - recurrent infections

Parenchymal Destruction
  • Lung Parenchyma
  • Made of thousands of acini (gas xchange units),
    looks like bunch of grapes
  • Each acinus contains respiratory bronchioles,
    alveolar ducts, alveolar sacs
  • Emphysema - destruction of alveolar walls and
    enlargement of terminal airspaces
  • As septal walls are destroyed, grapelike
    appearance becomes more rounded and surface area
    (for airway xchange) is reduced

Parenchymal Destruction
  • Inflammation
  • Important to progression of COPD
  • Inflammatory mediators and cellular components
    cause mucus hypersecretion and loss of alveolar
    structure and airway remodeling

Clinical Consequences
  • As result of morphologic change
  • Worsened obstruction
  • hyperinflation of the lungs
  • increased sputum production
  • reduced elastic recoil
  • recurrent respiratory infections
  • altered gas exchange
  • Respiratory muscle fatigue, ventilatory
    disorders, cardiovascular compromise, and poor

Comparison with Asthma
  • Mechanism of Inflammation varies
  • Asthma - eosinophilic inflammation
  • Chronic Bronchitis - Neutrophilic
  • Mucus Hypersecretion and cough
  • important to chronic bronchitis, not to emphysema
  • may be seen in acute asthma attack
  • With bronchodilators, FEV1 is more reversible in
    asthma than COPD
  • Table 24-1

DiagnosisPatient Assessment
  • Guidelines- table 24-2 24-3(
  • Spirometry - for diagnosis and assessment of
    disease severity
  • Diagnosis based on subjective and objective data
  • Tobacco use - raises suspicion
  • Careful medical history
  • symptoms of cough, sputum production, dyspnea,
  • Early detection and intervention is important
  • Once changes occur, irreversible

DiagnosisPatient Assessment
  • Cough an sputum production may be present for
    years prior to airflow limitations (and not
    everyone w/symptoms go on to COPD)
  • DOE (Dyspnea on Exertion) may not be present
    until sixth or seventh decade
  • PE -
  • early on, may not have physical signs
  • Later on, barrel chest, rales, rhonchi, prolonged
    expiratory phase, decreased breath sounds,
    cyanosis, edema, pursed lip breathing

Spirometry Testing
  • Should be performed when pt is stable
  • Indicators for COPD
  • Decreased FEV1
  • Reduction in FEV1 to FVC ratio to lt75
  • PEF (peak expiratory flow) roughly correlate to
    FEV1, However in advanced emphysema, FEV1 can be
    quite impaired and PEF only moderately affected

Spirometry Testing
  • IF FEV1 lt1 L
  • 5 year Mortality 50
  • IF FEV1 lt 0.5 L
  • Mean survival lt 2yrs

ABG Testing
  • In stable condition
  • pH is normal
  • hypoxemia present
  • mild to moderate hypercapnia (carbon dioxide
    retention) , gets worse when FEV lt 0.8L
  • During acute exacerbation
  • pH is acidotic
  • Hypercapnia worsens

Other Testing
  • HB and HCT
  • May be elevated secondary to chronic hypoxia
  • Alpha1-antitrypsin concentration
  • Should be determined for pt lt50 yo developing
    COPD, or if have emphysema w/o smoking history,
    patients with family history of deficiency

Management Strategies
  • Table 24-4

Natural Course
  • Generally develops and worsens over 20-40 yrs
  • Influenced by genetic predisposition, exposure to
    inhaled irritants (tobacco smoke, pollutants),
    and repeated infections
  • Typical course for smoker
  • Asymptomatic for first two decades (may have more
    frequent viral or bacterial infections)
  • After 25-30 yrs, dyspnea may be noted and
    morning cough, irreversible damage has occurred

General Management
  • Goals Table 24-5
  • Generally, benefits of medication are less in
    COPD than in Asthma
  • Side effects are more frequent
  • comorbidities are more common and complicate
  • Functional Status Goal
  • Asthma- normal functioning, including exercise
  • COPD- less ambitious, e.g. walk through house w/o
    severe SOB

General Management
  • PFT Goal
  • Asthma- gt80 of patients predicted normal or
    personal best (green zone)
  • COPD- may have baseline lt50 of normal and this
    patient personal best may be in the red zone
  • Overall, the goal is to obtain the best possible
    QOL that is attainable

General Management
  • Assess and monitor disease
  • Reduce the risk factors
  • smoking, immunize as appropriate

General Management
  • Manage stable COPD
  • pulmonary rehab (table 24-6), proper coughing
    techniques, postural drainage, chest percussion
    (mobilize mucus-may not be that effective)
  • Manage exacerbations
  • Adequate hydration (not done in stable COPD)
  • guaifenesin and iodide - supposed to thin
    secretions - not effective

  • Current Medications do not alter progression of
  • Symptomatic relief and minimize airflow
  • Realistic goals should be set
  • FEV1 (although pts may not have noticeable
    change), dyspnea, exercise tolerance, QOL,
    exacerbation rates,
  • Other Measures-utilization of healthcare,
  • Therapy trials should be continued for weeks to
    months before assessing efficacy

Pharmacotherapy Bronchodilators
  • Reduce bronchial airway smooth muscle tone
  • patients are able to exhale more fully
  • None shown more effective than another
  • Inhalation better than oral route
  • First Line
  • Short Acting B2-agonist or anticholinergic
    (ipraptropium)-variable effect -some pts may have
    better outcome from one over the other
  • Should be given prn or scheduled, dependent on
    symptom frequency

Pharmacotherapy Bronchodilators
  • While gold standard for significant improvement
    is 12 to15 FEV1 improvement
  • patients often feel better because now able to
    empty the lungs and reduce thoracic overinflation
  • Long acting bronchodilators
  • easier than short-acting

Pharmacotherapy Bronchodilators
  • Theophylline - Long debated
  • Was assumed that only functioned as
    bronchodilator (not that effective)
  • Other mechanisms - stimulate diaphragm
    contractility and anti-inflammatory effects
  • When Theo withdrawn, pts can deteriorate
  • Reserved as near-last therapy

Pharmacotherapy Systemic Corticosteroids (CS)
  • Controversial and disappointing
  • Only 10-30 benefit
  • Difficult to determine who will benefit
  • Risk is substantial
  • Only indicated for short-term use during acute

Pharmacotherapy Inhaled Corticosteroids (CS)
  • Minimizes risks compared to systemic CS
  • Does not seem to deter progression of disease
  • Recommended in symptomatic patients with FEV1
    lt50 and repeated exacerbations requiring
    antibiotics or systemic CS
  • No established role for cromolyn or leukotriene

Pharmacotherapy Antibiotics (abx)
  • Patients with COPD are chronically colonized
  • 50 of Acute exacerbations of COPD are infectious
  • Virus, gram (streptococcus pneumoniae), gram -
    (Haemophilus influenza)
  • 1st Amoxicillin, bactrim, doxycycline
  • 2nd B-lactamase stable penicillins, 2nd/3rd
    generation cephalosporins, extended macrolides,
    anti-pneumococcal FQ
  • No evidence of benefit from prophylactic abx

Pharmacotherapy (cont)
  • Antibiotics should be given when documented
    infection (gram stain, CXR shows pneumonia)
  • Oxygen therapy
  • well documented efficacy
  • O2 saturation gt90
  • Alpha1 antitrypsin
  • Is available for those with deficiency
  • not well tolerated
  • expensive

Acute Exacerabtions
  • 2 to 4 acute exacerbations yearly
  • increased dyspnea, cough, sputum production
  • May require hospitalization
  • Treatment
  • Supplemental oxygen
  • intense bronchodilator regimens
  • systemic CS, abx

Section 1
  • What sign does EB have that is typical of early
    stage of COPD
  • What breath sounds suggest increased mucus
  • What risk category is EB according to GOLD?
  • Can lung damage occur before COPD symptoms

Section 2
  • What is the primary risk factor present in EB?
    Other risk factors?
  • What is the acceleration of FEV1 decline that
    occurs with smoking?
  • What are other environmental causes of COPD?
  • What is a pack-year?

Section 3
  • Is there overlap between chronic bronchitis and
  • Should we test EB for Alpha1 antitrypsin?

Section 4
  • What is the gold standard for assessment and
    staging of COPD severity?

Section 5
  • What are goals for EB?
  • What should education strategy include for EB?

Section 6
  • What is the only intervention with beneficial
    impact on COPD progression?
  • What pharmacotherapy can be considered for
    smoking cessation?

Section 7
  • Which vaccinations should be considered for EB?
  • How many people die from the Flu every year?
  • Does lung disease put you at higher risk of death
    from flu?
  • How often should flu vaccine be given to COPD
  • Is nasal flu vaccine an option for EB?

Section 7
  • What does the 23 in Pneumovax 23 stand for?
  • How often should Pneumovax be administered to pts
    with COPD?

Section 8
  • What does EB productive cough indicate?
  • What pharmacologic therapy has been demonstrated
    to modify the progressive decline in lung
    function found in COPD?
  • What is the primary pharmacologic therapy for
  • Can subjective benefit be seen with
    bronchodilators without objective benefit (e.g.

Section 8
  • How do the B2 agonists produce bronchodilation?
  • Are bronchodilators more effective in asthma or
    COPD and why?
  • Which route of delivery is more effective for
    bronchodilators, oral or inhaled, and why?
  • What is the onset of action of B2 agonists
    ipraptropium, when do they reach maximal
    effectiveness, what is duration of action?

Section 8
  • What are some common adverse effects found with
    B2 agonists?
  • How do the anticholinergics (ipraptropium) work
    in bronchodilation?
  • How does the bronchodilation of anticholinergics
    compare to B2 agonists?
  • What is the primary inhaled anticholinergic in

Section 8
  • What is typical starting dose of ipraptropium,
    maximal dose?
  • What are some side effects of inhaled
    anticholinergics (ipraptropium)?
  • What structural feature decreases absorption
    through lung tissue thereby decreasing systemic
  • What are other anticholinergics that have been
    used clinically in COPD?

Section 8
  • How does atropine compare to ipraptropium as far
    as Side effects and why?

Section 9
  • What tests can help us to determine whether B2
    agonists or anticholinergics should be used in pt
    with COPD?
  • How long should drug trial be conducted to
    determine efficacy in a patient?
  • If a partial response is obtained after 2 weeks,
    how should dosage be increased?
  • What is advantage of B2 agonist over

Section 10
  • According to guidelines, should inhaled therapy
    be prescribed on prn or routine basis?

Section 11
  • What symptoms does EB have that are consistent
    with chronic bronchitis (CB)?
  • What organisms are colonized in patients with CB?
  • What leads to pulmonary hypertension?
  • What is cor pulmonale?

Section 12
  • What does an FEV1 of 1.5L indicate as far as
    severity of disease?
  • Why hasnt the FVC declined as much as FEV1 in
  • What is the change in FEV1 with bronchodilator
    therapy and is this significant?
  • What is the definition of reversible airflow
    obstruction with use of bronchodilator?

Section 12
  • What is alternate absolute improvement in FEV1
    that can be considered significant?
  • Does improvement on spirometry always correlate
    to patients QOL?

Section 15
  • What is the advantage of using combination
  • Are long acting B2 agonists superior to short
    acting B2 agonists in COPD?
  • Are higher than recommended doses of salmeterol
    and formoterol useful and safe?
  • Can the long-acting B2 agonists be used as prn

Section 15
  • How does tiotropium differ from ipraptropium in
    mechanism of action?
  • How often is tiotropium dosed?
  • How does tiotropium compare to ipraptropium in
  • In clinical studies, how does tiotropium (18 mcg
    daily) compare to salmeterol (50 mcg BID)?

Section 15
  • When should theophylline (T) be considered in
    patient with COPD?
  • List some downsides to using T
  • What is target serum concentration of T?
  • How long should theophylline trial continue?
  • What did one study find when patients
    discontinued theophylline?
  • What are possible MofA of T?

Section 16
  • List signs of theophylline (T) toxicity in CK
  • How much is T concentration increased with
    concomitant use of Ciprofloxacin?

Section 17
  • What are alternative treatments for elevated
    theophylline (T) concentration?

Section 18
  • Why isnt long-term treatment with systemic
    corticosteroids (SC) recommended?
  • What percentage of patients experience a clinical
    response to SC?
  • What occurred in one study which withdrew SC in
    patients with COPD? Reference 120

Section 19
  • What did a meta-analysis find regarding effect of
    inhaled corticosteroids (IC) on FEV1?
  • What did one study find regarding d/c of IC?
  • Do IC modify the progression of COPD?
  • Why are IC less effective in COPD than asthma?
  • According to GOLD, when should IC be used?
  • How long should therapeutic trial of IC be

Section 20
  • What did the TRISTAN study find in regards to
    efficacy of salmeterol(S)/fluticasone(F)/ SF?

Section 22
  • If AZ exacerbation continues, what could develop?
  • What is the mortality rate for patients requiring
    hospitalization? 1yr mortality rate? Risk of
  • What are primary treatment of acute COPD?
  • How much supplemental O2 should be used?

Section 22
  • What are maximal doses of B2 agonists and
  • Can intravenous theophylline be used in acute
  • What did the SCCOPE trial find
  • regarding treatment failures?
  • 2 week vs 8 week regimen?
  • Can switching to inhaled corticosteroid aid in
    tapering of systemic corticosteroid?

Section 23
  • How often are COPD exacerbations have an
    infectious bacterial nature?
  • When are abx most beneficial?
  • What organisms should be covered by abx therapy?

(No Transcript)